Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

450
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
450
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

659
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
659

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levosimendan for acute right heart failure in COVID-19: another arrow in our quiver?

European review for medical and pharmacological sciences·2022
Same author

Free light chains a novel biomarker of cardiovascular disease. A pilot study.

European review for medical and pharmacological sciences·2019
Same author

The effects of remote ischaemic preconditioning on coronary artery function in patients with stable coronary artery disease.

International journal of cardiology·2017
Same author

[Ranolazine in the treatment of chronic stable angina].

La Clinica terapeutica·2012
Same author

Statins and coronary artery disease: clinical evidence and future perspective.

Minerva cardioangiologica·2012
Same author

[High-sensitivity troponin assay: biochemistry and clinical application].

Minerva medica·2011

Related Experiment Video

Updated: May 5, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

What's new about clopidogrel.

P Cialdella1, M Gustapane, C Camaioni

  • 1Institute of Cardiology, Catholic University, Rome, Italy - lmbiasucci@virgilio.it.

Minerva Cardioangiologica
|November 21, 2013
PubMed
Summary
This summary is machine-generated.

Clopidogrel resistance, often due to genetic factors or proton pump inhibitor (PPI) interactions, can lead to treatment failure. Doubling the clopidogrel dose effectively reduces stent thrombosis with minimal bleeding risk.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Related Experiment Videos

Last Updated: May 5, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Area of Science:

  • Pharmacology
  • Cardiology
  • Genetics

Background:

  • Clopidogrel is a crucial antiplatelet medication for acute coronary syndromes and post-stent implantation.
  • Therapy failure, primarily stent thrombosis, occurs despite clopidogrel use, linked to genetic variations and drug interactions.
  • CYP2C19 genetic mutations and proton pump inhibitor (PPI) interactions can impair clopidogrel activation.

Purpose of the Study:

  • To review current knowledge on clopidogrel resistance and its management.
  • To evaluate the clinical relevance of PPI interactions with clopidogrel.
  • To discuss strategies for overcoming clopidogrel resistance.

Main Methods:

  • Literature review of studies on clopidogrel efficacy, resistance, and drug interactions.
  • Analysis of genetic factors (CYP2C19) affecting clopidogrel metabolism.
  • Evaluation of proton pump inhibitor (PPI) interaction studies.

Main Results:

  • Recent evidence suggests PPI interaction with clopidogrel may not be clinically significant.
  • Variability in assays limits reliance on patient genotyping for clopidogrel response.
  • A double clopidogrel dose is effective in preventing cardiovascular events and reducing stent thrombosis, with a slight increase in bleeding.

Conclusions:

  • Clopidogrel resistance remains a concern, influenced by genetics and drug interactions.
  • Current evidence questions the clinical impact of PPIs on clopidogrel efficacy.
  • Therapeutic strategies, including dose adjustment, are being explored to optimize clopidogrel therapy.